Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid

International Journal of Dermatology

Volumn 47, Issue 3, 2008, Pages 225-228

  Feng, Suying ^a   Wu, Qinxue ^a   Jin, Peiying ^a   Lin, Lin ^a   Zhou, Wuqing ^a   Sang, Honggui ^a   Shao, Changgeng ^a  

^a INSTITUTE OF DERMATOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BULLOUS PEMPHIGOID ANTIGEN 1; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MEMBRANE PROTEIN; METHYLPREDNISOLONE; NICOTINAMIDE; PREDNISONE; TETRACYCLINE;

AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMIDESMOSOME; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PROTEIN DOMAIN; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; PROTEIN STRUCTURE, TERTIARY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 39449119708     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03473.x     Document Type: Article

References (10)

1. Giudice GJ, Emery DJ, Zelickson BD, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 5742-5750.
2. Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005; 37: 145-149.
3. Hata Y, Fujii Y, Tsunoda K, et al. Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression. J Dermatol Sci 2000; 23: 183-190.
4. Schmidt E, Obe K, Brocher EB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174-178.
5. Amo Y, Ohkawa T, Tatsuta M, et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2001; 26: 14-18.
6. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30: 224-232.
7. Mariotti F, Grisso F, Terracina M, et al. Development of a novel system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151: 1004-1010.
8. Izumi T, Ichiki Y, Esaki C, et al. Monitoring of ELISA for anti-BP180 antibodies: Clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. J Dermatol 2004; 31: 383-391.
9. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102: 878-881.
10. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16a and C-terminal domains of the 180.kDa BP antigen (BP180): Immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol 1998; 139: 365-370.